Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

Figure 1

Recurrence-free survival (RFS) of stage II-III colorectal cancer patients according to the CpG island methylation phenotype (CIMP). (A) Kaplan-Meier curves for RFS of patients treated by surgery alone. The three-year RFS for CIMP-high and CIMP-low/negative groups was 71.4% and 86.5%, respectively. (B) Kaplan-Meier curves for the RFS of patients treated with surgery and fluoropyrimidine-based adjuvant chemotherapy. The three-year RFS for CIMP-high and CIMP-low/negative groups was 100% and 82.4%, respectively.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us